DINUTUXIMAB BETA
Information current as at: 1 May 2025
The pharmaceutical company has withdrawn their submission for this medicine prior to the medicine being considered at the PBAC meeting.
PBAC meeting date: March 2020
Submission Details
- Brand name:
-
- Qarziba®
- Pharmaceutical company:
- EUSA Pharma (UK) Ltd
- Condition/indication:
(therapeutic use) -
- Neuroblastoma
- PBAC Submission type:
- New listing (Major)
- Comment:
- Item withdrawn
- Related medicines:
- --
Progress Details
-
Submission received for: - March 2020 PBAC meeting
-
Opportunity for consumer comment: - Open 24/12/2019 and close 12/02/2020 (see PBS Website)
-
PBAC meeting: - Held on 11/03/2020
-
PBAC outcome published: - Not Applicable (see PBAC Outcomes)
-
Lodgement of required documentation: - Not applicable
-
Agreement to listing arrangements: - Not applicable
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a126
Page last updated: 31 October 2024